A vaccine developed by the modern biotechnology company, in collaboration with the United States National Institutes of Health (NIH), generated a “robust” immune response by stopping the replication of COVID-19 in the lungs and nose of primates, according to results published in this tuesday (28).
This is one of the two western vaccines, together with the one developed by the University of Oxford in partnership with the Australian laboratory AstraZeneca, which started to be tested on a large scale. The United States has invested nearly $ 1 billion to support research.
Seven out of eight monkeys vaccinated in this study and exposed four weeks later to the new coronavirus did not register a detectable replication of the pathogen in their lungs two days later, and none of the eight animals had the virus in their nose, according to the results published this week. in the medical journal New England Journal of Medicine.
“The first time that an experimental vaccine against COVID-19 tested on primates shows its ability to produce rapid viral control in the upper airways,” the NIH said in a statement.
The scientists noted that the vaccine developed by Oxford had no effect on the amount of virus in the nose in monkeys.
Reducing the amount of virus in the lungs would make the disease less aggressive, while decreasing the number of viruses in an infected person’s nose would limit the potential for contamination to other beings.
Despite the hopeful results, only tests on humans that are underway will actually prove the vaccine’s effectiveness.
The Oxford / AstraZeneca vaccine, which is being tested in Brazil, may have definitive results starting in September. For Moderna, the forecast is October.